Glenmark gains on receiving final approval from USFDA for Desonide Cream

25 Jul 2017 Evaluate

Glenmark Pharmaceuticals is currently trading at Rs. 693.60, up by 4.70 points or 0.68% from its previous closing of Rs. 688.90 on the BSE.

The scrip opened at Rs. 696.60 and has touched a high and low of Rs. 699.95 and Rs. 691.15 respectively. So far 5,727 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 993.00 on 01-Nov-2016 and a 52 week low of Rs. 600.00 on 29-May-2017.

Last one week high and low of the scrip stood at Rs. 713.50 and Rs. 685.90 respectively. The current market cap of the company is Rs. 19,571.00 crore.

The promoters holding in the company stood at 46.50%, while Institutions and Non-Institutions held 40.80% and 12.70% respectively.

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for Desonide Cream, 0.05%, the generic version of Desonide Cream, 0.05% of Perrigo New York Inc.

According to IMS Health sales data for the 12 month period ending May 2017, the Desonide Cream, 0.05% market achieved annual sales of approximately $44.6 million.

Glenmark’s current portfolio consists of 120 products authorized for distribution in the US marketplace and 65 ANDA’s pending approval with the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.


Glenmark Pharma Share Price

1079.55 8.25 (0.77%)
25-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1520.55
Dr. Reddys Lab 6217.15
Cipla 1405.40
Zydus Lifesciences 953.50
Lupin 1589.10
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.